ProfileGDS5678 / 1448843_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 69% 68% 67% 68% 68% 60% 68% 67% 68% 68% 68% 68% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.1050367
GSM967853U87-EV human glioblastoma xenograft - Control 24.3136869
GSM967854U87-EV human glioblastoma xenograft - Control 34.1729168
GSM967855U87-EV human glioblastoma xenograft - Control 44.093767
GSM967856U87-EV human glioblastoma xenograft - Control 54.1215368
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1972768
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6601660
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1394968
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0708667
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1485468
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.1947168
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.203368
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1894668
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3112570